This indicates that Gilteritinib has good efficacy and safety for FLT3-mutated AML, providing a better choice for the subsequent treatment of AML patients, especially when formulating long-term treatment plans [41]. The gene discussed is FLT3; the disease is acute myeloid leukemia.